XORTX Announces Re-filing of YE 2023 and Q2 2024 MD&A

7 days ago

CALGARY, Alberta, Sept. 12, 2024 ( GLOBE NEWSWIRE ) -- XORTX Therapeutics Inc. ( "XORTX" or the "Company" ) ( NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU ) , a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that ...

Ticker	Sentiment	Impact
XRTX	Somewhat Bullish	16 %